Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour p53 mutations exhibit promoter selective dominance over wild type p53.

Oncogene - 7 Mar 2002

Monti Paola, Campomenosi Paola, Ciribilli Yari, Iannone Raffaella, Inga Alberto, Abbondandolo Angelo, Resnick Michael A, Fronza Gilberto

Abstract excerpt

The tumour suppressor gene p53 is frequently mutated in human cancer. Tumour derived p53 mutants are usually transcriptionally inactive, but some mutants retain the ability to transactivate a subset of p53 target genes. In addition to simple loss of function, some p53 mutants may be carcinogenic through a dominant negative mechanism. Aiming at a more general classification of p53 mutants into predictive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Mutation

Share to Promoter Regions, Genetic

Share to Response Elements

Share to Transcriptional Activation

Source

Identifiers

PMID: 11896595
DOI: 10.1038/sj.onc.1205250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour p53 mutations exhibit promoter selective dominance over wild type p53.PMID 11896595Read ↗

Dominant-negative p53 mutations selected in yeast hit cancer hot spots.Semantic proximity Read ↗

p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.Semantic proximity Read ↗

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.Semantic proximity Read ↗

p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors.Semantic proximity Read ↗

Simple identification of dominant p53 mutants by a yeast functional assay.Semantic proximity Read ↗

Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.Semantic proximity Read ↗

Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activitySemantic proximity Read ↗

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.Semantic proximity Read ↗

Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.Semantic proximity Read ↗

Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer.Semantic proximity Read ↗

Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.Semantic proximity Read ↗

Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.